Literature DB >> 8642801

Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases.

M Esler1.   

Abstract

Sympathetic nervous system activation has been documented in several cardiovascular disorders. In some, characterized by cardiac failure and portal hypertension accompanying hepatic cirrhosis, the sympathetic nervous stimulation is reflex and, to some extent, compensatory but has adverse consequences. For example, in cardiac failure, the sympathetic nerves of the heart are preferentially stimulated, providing adrenergic support to the failing myocardium but at the probable cost of arrhythmogenesis and progressive myocardial deterioration. The sympathetic activation present in patients with essential hypertension, which involves the sympathetic outflows to skeletal muscle, heart, and kidneys and is seen particularly in younger patients, differs from these examples in that the sympathetic nervous stimulation is apparently not reflex and the primary cause is unknown. There is, however, evidence that activation of forebrain pressor noradrenergic nuclei may be of importance as an underlying central nervous system mechanism. This sympathetic nervous stimulation in patients with essential hypertension, in addition to initiating the blood pressure elevation, may also contribute to the commonly associated metabolic abnormalities of insulin resistance and hyperlipidemia, with neural vasoconstriction having metabolic consequences, impairing glucose delivery and causing insulin resistance in muscle, and retarding postprandial clearing of lipids in liver. Trophic effects of sympathetic activation on cardiovascular growth are claimed but have yet to be demonstrated conclusively in humans.

Entities:  

Mesh:

Year:  1995        PMID: 8642801

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  23 in total

1.  Effects of chronic sympatho-inhibition on reflex control of renal blood flow and plasma renin activity in renovascular hypertension.

Authors:  S L Burke; R G Evans; G A Head
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 2.  New approaches to quantifying sympathetic nerve activity.

Authors:  Sandra L Burke; Elisabeth Lambert; Geoffrey A Head
Journal:  Curr Hypertens Rep       Date:  2011-06       Impact factor: 5.369

3.  Switch to glutamate receptor 2-lacking AMPA receptors increases neuronal excitability in hypothalamus and sympathetic drive in hypertension.

Authors:  De-Pei Li; Hee Sun Byan; Hui-Lin Pan
Journal:  J Neurosci       Date:  2012-01-04       Impact factor: 6.167

4.  Combined Aliskiren and L-arginine treatment reverses renovascular hypertension in an animal model.

Authors:  Renata V Tiradentes; Cintia H Santuzzi; Erick Rg Claudio; Vinicius Mengal; Nyam F Silva; Henrique A F Neto; Nazaré S Bissoli; Glaucia R Abreu; Sonia A Gouvea
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

Review 5.  Fifty years of microneurography: learning the language of the peripheral sympathetic nervous system in humans.

Authors:  J Kevin Shoemaker; Stephen A Klassen; Mark B Badrov; Paul J Fadel
Journal:  J Neurophysiol       Date:  2018-02-07       Impact factor: 2.714

Review 6.  Glutamatergic Regulation of Hypothalamic Presympathetic Neurons in Hypertension.

Authors:  De-Pei Li; Hui-Lin Pan
Journal:  Curr Hypertens Rep       Date:  2017-09-19       Impact factor: 5.369

7.  Sympathetic responses to repetitive trans-spinal magnetic stimulation.

Authors:  Roger J Paxton; Matthew P Malcolm; Sean A Newsom; Jennifer C Richards; Grant M Rynn; Christopher Bell
Journal:  Clin Auton Res       Date:  2010-11-27       Impact factor: 4.435

Review 8.  The role of the central nervous system in hypertension.

Authors:  J M Wyss; S H Carlson
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

9.  Increased plasma norepinephrine levels in previously pre-eclamptic women.

Authors:  K H Lampinen; M Rönnback; P-H Groop; M G Nicholls; T G Yandle; R J Kaaja
Journal:  J Hum Hypertens       Date:  2013-09-19       Impact factor: 3.012

Review 10.  Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

Authors:  Laurence Bodineau; Alain Frugière; Yannick Marc; Cédric Claperon; Catherine Llorens-Cortes
Journal:  Heart Fail Rev       Date:  2008-01-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.